DWDa Wang

Da Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Da Wang has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Dengyong Xu

    Department of Colorectal Surgery, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310016, P.R. China

    2 shared publications
  • Qian Lu

    Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China

    2 shared publications
  • Ruyun Cai

    Department of Colorectal Surgery, Sir Run Run Shaw Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China

    2 shared publications
  • Bing-Jun Bai

    Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou 310016, Zhejiang Province, China

    1 shared publication
  • Chuanxi Lai

    Department of Colorectal Surgery, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    1 shared publication
  • Chunliang Wang

    First Peoples Hosp Fuyang, Dept Colorectal Surg, Hangzhou 310022, Zhejiang, Peoples R China

    1 shared publication

Latest Publications

  • Open Access

    5‑Fluorouracil‑induced severe hyperlactatemic encephalopathy during chemotherapy for advanced colorectal cancer: Case reports and literature review

    by Yiping Jin, Xiaonan Xiang, Wei Zhang, Da Man, Dengyong Xu, Da Wang

    5‑Fluorouracil (5‑FU) is a key drug in the treatment of advanced colorectal cancer (CRC). Although 5‑FU is generally well tolerated, a small subset of patients may experience life‑threatening neurotoxicity. Among these complications, 5‑FU‑induced encephalopathy accompanied by severe hyperlactatemia is a particularly serious metabolic emergency. Impaired drug clearance, especially due to underlying renal insufficiency, may substantially increase this risk. In the present study, the cases of three patients with advanced CRC who developed acute, severe impairment of consciousness 48 h after receiving 5‑FU‑based chemotherapy were retrospectively reviewed. Clinical presentations ranged from aphasia and confusion to deep coma. All patients exhibited marked hyperlactatemia, with peak blood lactate levels of 18.0, 18.19 and 15.56 mmol/l for Cases 1, 2 and 3, respectively. A total of two patients had marked baseline renal impairment (one with chronic kidney disease, the other with end‑stage renal disease on maintenance hemodialysis). Neuroimaging (CT/CT perfusion/CT angiography/MRI) excluded acute cerebrovascular events in all cases. Chemotherapy was immediately discontinued and intensive supportive care was initiated. For the patient with anuric renal failure, early continuous venovenous hemofiltration was initiated. All three patients achieved complete neurological recovery and normalization of metabolic parameters. Notably, the hemodialysis‑dependent patient subsequently underwent successful 5‑FU rechallenge using a 50% dose reduction combined with prophylactic post‑chemotherapy hemodialysis, without recurrence of neurotoxicity. 5‑FU‑induced severe hyperlactatemic encephalopathy is a potentially fatal oncological emergency. Underlying renal impairment may lead to the accumulation of toxic metabolites. For patients presenting with extreme hyperlactatemia (>10 mmol/l) and profound impairment of consciousness, early initiation of continuous renal replacement therapy may be an effective strategy to resolve neurological dysfunction. In patients with end‑stage renal disease requiring subsequent fluoropyrimidine therapy, substantial dose reduction combined with prophylactic hemodialysis may offer a feasible rechallenge approach. Furthermore, clinicians must consider genetic mutations related to hepatotoxicity and nephrotoxicity. Evaluation of these organ‑vulnerability genes before chemotherapy warrants further clinical investigation to prevent severe toxicity.

  • Open Access

    Efficacy and safety of combining short-course neoadjuvant chemoradiotherapy with envafolimab in locally advanced rectal cancer patients with microsatellite stability: a phase II PRECAM experimental study

    by Fei Wang, Chuanxi Lai, Yiming Lv, Feixiang Zhang, Liming Shi, Yunfei Wang, Yanbin Shen, Lingna Xu, Peng Hu, Wen Tang, et al.

    Background: Conventional neoadjuvant chemoradiotherapy (nCRT) yields a pathologic complete response (pCR) rate of 15–30% for locally advanced rectal cancer (LARC). This study ventures to shift this paradigm by incorporating short-course nCRT with immunotherapy, specifically Envafolimab, to achieve improved treatment efficacy and possibly redefine the standard of care for LARC. Materials and methods: The PRECAM study is a prospective, single-arm, phase 2 clinical trial for LARC in patients with microsatellite stable (MSS) tumors. Participants received short-course radiotherapy (25Gy/5f), followed by two cycles of CAPEOX chemotherapy and six weekly doses of Envafolimab, a PD-L1 antibody, before total mesorectal excision surgery. The primary endpoint was the pCR rate. Results: From April to December 2022, 34 patients were enrolled, of whom 32 completed the study, each diagnosed with an MSS rectal adenocarcinoma. All patients underwent preoperative CRT combined with Envafolimab. Remarkably, a pCR rate of 62.5% (20/32) was attained, and a significant pathologic response rate of 75% (24/32) was achieved. Additionally, 21 of 32 participants achieved a neoadjuvant rectal (NAR) score below 8, suggesting an effective treatment response. Common adverse events included tenesmus (78.1%), diarrhea (62.5%), and leukocyte decrease (40.6%). Two Grade 3 adverse events were noted, one related to liver function abnormality and the other to a decrease in platelet count. Surgical procedures were performed in all cases, with minor complications, including ileus, infections, and anastomotic leakage. As of this report, there have been no reported cases of recurrence or death during the follow-up period, ranging from 12 to 20 months. Conclusion: In LARC patients exhibiting MSS tumors, combining short-course nCRT with Envafolimab demonstrated favorable efficacy, leading to a significant pCR rate. Minor adverse effects and surgical complications were observed. These preliminary but promising results underscore the potential of this approach and call for further exploration and validation through a randomized controlled trial.


  • Open Access

    Micro-power negative pressure wound technique reduces risk of incision infection following loop ileostomy closure

    by Deng-Yong Xu, Bing-Jun Bai, Lina Shan, Hui-Yan Wei, Deng-Feng Lin, Ya Wang, Da Wang

    BACKGROUND Prophylactic loop ileostomy is an effective way to reduce the clinical severity of anastomotic leakage following radical resection of rectal cancer. Incisional surgical site infection (SSI) is a common complication after ileostomy closure. AIM To evaluate the efficacy and safety of the micro-power negative pressure wound technique (MPNPWT) in preventing incisional SSI. METHODS This was a prospective, randomized controlled clinical trial conducted at a single center. A total of 101 consecutive patients who underwent ileostomy closure after rectal cancer surgery with a prophylactic ileostomy were enrolled from January 2019 to December 2021. Patients were randomly allocated into an MPNPWT group and a control group. The MPNPWT group underwent intermittent suturing of the surgical incision with 2-0 Prolene and was covered with a micro-power negative pressure dressing. The surgical outcomes were compared between the MPNPWT (n = 50) and control (n = 51) groups. Risk factors for incisional SSI were identified using logistic regression. RESULTS There were no differences in baseline characteristics between the MPNPWT (n = 50) and control groups (n = 51). The incisional SSI rate was significantly higher in the control group than in the MPNPWT group (15.7% vs 2.0%, P = 0.031). However, MPNPWT did not affect other surgical outcomes, including intra-abdominal complications, operative time, and blood loss. Postoperative hospital stay length and hospitalization costs did not differ significantly between the two groups (P = 0.069 and 0.843, respectively). None of the patients experienced adverse effects of MPNPWT, including skin allergy, dermatitis, and pain. MPNPWT also helped heal the infected incision. Our study indicated that MPNPWT was an independent protective factor [odds ratio (OR) = 0.005, P = 0.025)] and diabetes was a risk factor (OR = 26.575, P = 0.029) for incisional SSI. CONCLUSION MPNPWT is an effective and safe way to prevent incisional SSI after loop ileostomy closure.


  • Open Access

    Clinicopathological characteristics and prognosis of colon cancer with lung metastasis without liver metastasis: A large population-based analysis

    by Xiao Mm Wang, Ruihua Mm Qi, Ying Mm Xu, Xingang Mm Lu, Qing Mm Shi, Ya Mm Wang, Da Wang, Chunliang Mm Wang

    Distant metastasis explains the high mortality rate of colon cancer, in which lung metastasis without liver metastasis (LuM) is a rare subtype. This study is aimed to identify risk factors of LuM and LLM (lung metastasis with liver metastasis) from colon cancer, and to analyze the prognosis of patients with LuM by creating a nomogram. Patients’ information were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. Multivariable logistic regression analysis was used to determine the risk factors for LuM and LLM. Prognostic factors for cancer-specific survival (CSS) and overall survival (OS) were identified by multivariate Cox proportional hazards regression and nomogram models were established to predict CSS and OS. Multivariate logistic regression analysis showed that blacks, splenic flexure of colon tumor, tumor size >5 cm, T4, N3, and higher lymph node positive rate were associated with the occurrence of LuM. Meanwhile, age >65 years old, female, splenic flexure of colon, higher lymph node positive rate, and brain metastasis were independent risk factors for CSS. The C-index of the prediction model for CSS was 0.719 (95% CI: 0.691–0.747). In addition, age, primary site, tumor size, differentiation grade, N stage, and bone metastasis were significantly different between LuM and LLM. The nomograms we created were effective in predicting the survival of individuals. Furthermore, patients with LuM and LLM from colon cancer might require different follow-up intervals and examinations.


  • Open Access

    Construction and prognostic analysis of miRNA-mRNA regulatory network in liver metastasis from colorectal cancer

    by Ruyun Cai, Qian Lu, Da Wang

    Background: Colorectal cancer (CRC) is one of the most common cancers in the world, and liver metastasis is the leading cause of colorectal cancer-related deaths. However, the mechanism of liver metastasis in CRC has not been clearly elucidated.Methods: Three datasets from the Gene Expression Omnibus (GEO) database were analyzed to obtain differentially expressed genes (DEGs), which were subjected to functional enrichment analysis and protein-protein interaction analysis. Subsequently, mRNA-miRNA network was constructed, and the associated DEGs and DEMs were performed for prognostic analysis. Finally, we did infiltration analysis of growth arrest specific 1 (GAS1)-associated immune cells.Results: We obtained 325 DEGs and 9 differentially expressed miRNAs (DEMs) between primary CRC and liver metastases. Enrichment analysis and protein-protein interactions (PPI) further revealed the involvement of DEGs in the formation of the inflammatory microenvironment and epithelial-mesenchymal transition (EMT) during the liver metastases process in CRC. Survival analysis demonstrated that low-expressed GAS1 as well as low-expressed hsa-miR-33b-5p was a favorable prognostic indicator of overall survival. Further exploration of GAS1 revealed that its expression was interrelated with the infiltration of immune cells in tumor tissues.Conclusions: In summary, DEGs, DEMs, and their interactions found in liver metastasis of CRC may provide a basis for further understanding of the mechanism of CRC metastasis.


  • Open Access

    Construction and Prognostic Analysis of miRNA-mRNA Regulatory Network in Liver Metastasis from Colorectal Cancer

    by Ruyun Cai, Qian Lu, Da Wang

    Background: Colorectal cancer (CRC) is one of the most common cancers in the world, and liver metastasis is the leading cause of colorectal cancer-related deaths. However, the mechanism of liver metastasis in CRC hasn’t been clearly elucidated.Methods: Three datasets from the Gene Expression Omnibus (GEO) database were analyzed to obtain differentially expressed genes (DEGs), which were subjected to functional enrichment analysis and protein-protein interaction analysis. Subsequently, mRNA-miRNA network was constructed and the associated DEGs and DEMs were performed for prognostic analysis. Finally, we did infiltration analysis of GAS1-associated immune cells. Results: We obtained 325 DEGs and 9 differentially expressed miRNAs (DEMs) between primary CRC and liver metastases. Enrichment analysis and protein-protein interactions (PPI) further revealed the involvement of DEGs in the formation of the inflammatory microenvironment and epithelial-mesenchymal transition (EMT) during the liver metastases process in CRC. Survival analysis demonstrated that low-expressed GAS1 as well as low-expressed hsa-miR-33b-5p was a favorable prognostic indicator of overall survival. Further exploration of GAS1 revealed that its expression was interrelated with the infiltration of immune cells in tumor tissues. Conclusions: In summary, DEGs, DEMs and their interactions found in liver metastasis of CRC may provide a basis for further understanding of the mechanism of CRC metastasis.


  • Open Access

    Multidisciplinary evaluation of locally advanced leiomyosarcoma in the lower rectum: a case report and literature review

    by Dengyong Xu, Yiming Lv, Linlin Chen, Min Chen, Fei Wang, Zhangfa Song, Xuefeng Huang, Da Wang

    Rectal leiomyosarcoma is a rare neoplasm, and no standard therapeutic strategy has been established, other than surgical resection. The prognosis of advanced leiomyosarcoma in the rectum is poor. We describe a case of a 47-year-old man with a locally advanced rectal leiomyosarcoma who presented with anal bleeding and lower abdominal pain. After discussions by a multidisciplinary team (MDT), the patient received preoperative pelvic short-course radiotherapy followed by laparoscopic-assisted abdominoperineal resection. Adjuvant chemotherapy with doxorubicin and ifosfamide was administered postoperatively. Local recurrence was detected 13 months after the resection. The patient received chemotherapy with gemcitabine and docetaxel followed by radioactive particle implantation. Thereafter, apatinib was administered to gain systemic control. The patient died 24 months after the diagnosis. This case report draws attention to treatment with multidisciplinary therapy, as discussed by MDT, for rare locally advanced rectal leiomyosarcoma.